1,502 results match your criteria Expert Review of Clinical Immunology[Journal]


Tofacitinib for the treatment of rheumatoid arthritis: an update.

Authors:
Kunihiro Yamaoka

Expert Rev Clin Immunol 2019 Apr 18. Epub 2019 Apr 18.

a Department of Rheumatology and Infectious Diseases , Kitasato University School of Medicine , 1-15-1 Kitasato, Minami-ku, Sagamihara , Kanagawa , 252-0374 Japan.

Introduction: Tofacitinib selectively inhibits the Janus kinases, intracellular tyrosine kinases that are activated by cytokines involved in the pathophysiology of rheumatoid arthritis. Areas covered: Clinical trials of tofacitinib have revealed an anti-rheumatic effect of monotherapy and combination therapy with methotrexate (MTX). Post-hoc analysis of those clinical trials and real-world experiences will be reviewed to explore tofacitinib's efficacy and safety. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1607298DOI Listing
April 2019
2 Reads

Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.

Expert Rev Clin Immunol 2019 Apr 16:1-8. Epub 2019 Apr 16.

a The First Department of Internal Medicine , University of Occupational and Environmental Health , Kitakyushu, Fukuoka , Japan.

Introduction: JAK, which constitutively binds to some cytokine receptors, plays an important role in cytokine signaling. While JAK is comprised of JAK1, JAK2, JAK3, and Tyk2, more than 40 types of cytokines transmit signals through JAK. Baricitinib is reported to be highly effective in the treatment of rheumatoid arthritis (RA) and is the second drug launched as a JAK inhibitor for RA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1608821DOI Listing
April 2019
1 Read

Novel understanding of high mobility group box-1 in the immunopathogenesis of incisional hernias.

Expert Rev Clin Immunol 2019 Apr 16:1-10. Epub 2019 Apr 16.

a Departments of Clinical and Translational Science , Creighton University School of Medicine , Omaha , USA.

Introduction: Incisional hernias (IH) arise as a complication of patients undergoing laparotomy. Current literature has assessed the role of extracellular matrix (ECM) disorganization, alterations in type I and type III collagen, matrix metalloproteinases, and tissue inhibitors of metalloproteases on IH. However, there is limited information on the underlying molecular mechanisms that lead to ECM disorganization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1608822DOI Listing

Cannabis allergy: what the clinician needs to know in 2019.

Expert Rev Clin Immunol 2019 Apr 4:1-8. Epub 2019 Apr 4.

a Department of Immunology-Allergology-Rheumatology , Antwerp University Hospital, University of Antwerp , Antwerp , Belgium.

Introduction: Although the use of cannabis dates back millennia, the first description of cannabis allergy is relatively recent (1971). Recent large-scale data show that cannabis allergy can manifest severe and generalized symptoms with extensive cross-reactions. Thus, it is essential to become familiarized with its clinical presentation, diagnostic aids, and adequate therapeutic guidance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1600403DOI Listing
April 2019
3 Reads

Clinical outcomes and predictors of maternal and fetal complications in pregnancies of patients with systemic lupus erythematosus.

Expert Rev Clin Immunol 2019 Apr 1:1-11. Epub 2019 Apr 1.

a Department of Medicine - DIMED, Division of Rheumatology , University of Padova , Padova , Italy.

Introduction: Systemic Lupus Erythematosus (SLE) mostly affects women during their childbearing years. Fertility is preserved in SLE patients, but pregnancy is often characterized by a high number of maternal and fetal complications. Adverse pregnancy outcomes (APO) have been widely studied over the last decades and several investigators have focused on the potential clinical and serological predictors of maternal and fetal complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1601557DOI Listing
April 2019
2 Reads

Epithelial physical barrier defects in chronic rhinosinusitis.

Expert Rev Clin Immunol 2019 Mar 29:1-10. Epub 2019 Mar 29.

a Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital , Capital Medical University , Beijing , China.

Introduction: Chronic rhinosinusitis (CRS) is a common upper airway disease with a prevalence of greater than 10% of the general population. Although the pathogenesis of CRS remains poorly understood, there is growing evidence indicating that epithelial physical barrier defects play an important role in CRS pathogenesis. Areas covered: Epithelial physical barriers are maintained by various intercellular junctions, especially tight junctions (TJs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1601556DOI Listing
March 2019
1 Read

Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.

Authors:
Lluís Puig

Expert Rev Clin Immunol 2019 Mar 28:1-9. Epub 2019 Mar 28.

a Department of Dermatology, Hospital de la Santa Creu i Sant Pau , Universitat Autònoma de Barcelona , Barcelona , Spain.

Introduction: Guselkumab is a subcutaneously administered monoclonal antibody that targets the IL-23p19 cytokine subunit and has been approved by the US FDA and the EMA for the treatment of moderate-to-severe psoriasis in adult patients. Areas covered: This review outlines the pharmacologic properties, efficacy and safety of guselkumab for the treatment of moderate-to-severe plaque psoriasis in adults. Expert opinion: In clinical trials, guselkumab markedly improved disease, regardless of topographical locations and patient subpopulations, with corresponding improvements in quality of life measures, and was generally well tolerated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1601014DOI Listing
March 2019
1 Read

Mediterranean fever gene variants and colchicine therapy in periodic fever, aphthous stomatitis pharyngitis, adenitis syndrome in a Mediterranean region.

Expert Rev Clin Immunol 2019 May 19;15(5):571-575. Epub 2019 Mar 19.

b Faculty of Medicine, Department of Pediatrics, Division of Pediatric Infectious Disease , Cukurova University , Adana , Turkey.

Objectives: Periodic fever, aphthous stomatitis, pharyngitis, adenitis syndrome is characterized by recurrent episodes of fever. Attenuated disease severity was considered in patients with Mediterranean fever (MEFV) gene variations. Corticosteroids are highly effective in controlling the symptoms but usually cause more frequent episodes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1591275DOI Listing
May 2019
5 Reads

Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Expert Rev Clin Immunol 2019 Mar 18:1-18. Epub 2019 Mar 18.

e Department of Otolaryngology , Beijing Electric Power Hospital , Beijing , China.

Introduction: An increasing number of patients present with multiple symptoms affecting many organs including the brain due to multiple mediators released by mast cells. These unique tissue immune cells are critical for allergic reactions triggered by immunoglobulin E (IgE), but are also stimulated (not activated) by immune, drug, environmental, food, infectious, and stress triggers, leading to secretion of multiple mediators often without histamine and tryptase. The presentation, diagnosis, and management of the spectrum of mast cell disorders are very confusing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1596800DOI Listing
March 2019
1 Read

Implications for redefining the dense fine speckled and related indirect immunofluorescence patterns.

Expert Rev Clin Immunol 2019 May 29;15(5):447-448. Epub 2019 Mar 29.

d Cumming School of Medicine , University of Calgary , Calgary , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1596802DOI Listing

The long-awaited 'pseudo-DFS pattern'.

Expert Rev Clin Immunol 2019 May 29;15(5):445. Epub 2019 Mar 29.

a Laboratorio Immunologia e Allergologia , Ospedale S. Giovanni di Dio, Firenze , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1596801DOI Listing
May 2019
2 Reads

Predicting uveitis in juvenile idiopathic arthritis: from biomarkers to clinical practice.

Expert Rev Clin Immunol 2019 Mar 15:1-10. Epub 2019 Mar 15.

a Department of Ophthalmology, University Medical Center Utrecht , Utrecht University , Utrecht , The Netherlands.

Introduction: Uveitis is a sight-threatening eye inflammation and common manifestation of juvenile idiopathic arthritis (JIA). New biomarkers that can predict uveitis are needed to alleviate personalized clinical screening. In this review, we outline clinical and molecular risk factors for uveitis and discuss their putative biology and value for clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1593139DOI Listing
March 2019
1 Read

The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target.

Expert Rev Clin Immunol 2019 Mar 15:1-9. Epub 2019 Mar 15.

c Division of Rheumatology and Clinical Immunology, Department of Medicine , Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , MA , USA.

Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibodies production and immune complex deposition with systemic clinical manifestations. Interleukin (IL)-17-producing cells play a crucial role in disease pathogenesis and represent an attractive therapeutic target. Areas covered: This review provides an update on the possibility of targeting IL-17 in SLE. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1593141DOI Listing
March 2019
6 Reads

Prediction of treatment outcome and relapse in inflammatory bowel disease.

Expert Rev Clin Immunol 2019 Mar 15:1-11. Epub 2019 Mar 15.

c Department of Gastroenterology and Hepatology , Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama , Japan.

Introduction: Prediction of treatment outcome and clinical relapse in patients with inflammatory bowel disease (IBD), either ulcerative colitis (UC) or Crohn's disease (CD), is particularly important because therapeutics for IBD are not always effective and patients in remission could frequently relapse. Because undergoing endoscopy for the purpose is sometimes invasive and burdensome to patients, the performance of surrogate biomarkers has been investigated. Areas covered: We particularly featured the performance of patient symptoms, blood markers including C-reactive protein (CRP), fecal markers including fecal calprotectin (Fcal) and fecal immunochemical test (FIT) for prediction of endoscopic mucosal healing (MH) and prediction of relapse. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1593140DOI Listing
March 2019
9 Reads

Epicutaneous peanut patch device for the treatment of peanut allergy.

Expert Rev Clin Immunol 2019 May 27;15(5):449-460. Epub 2019 Mar 27.

a Department of Allergy and Immunology , Centre Hospitalier Universitaire Sainte-Justine , Montreal , QC , Canada.

Introduction: Food allergy prevalence has increased in recent decades, which has mobilized efforts to develop treatment alternatives. Epicutaneous immunotherapy (EPIT) is a novel method that involves transdermal administration of peanut allergen with the objective to induce tolerance. Recent clinical trials have shown its efficacy at increasing the eliciting dose in children with a favorable safety profile. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1593138DOI Listing
May 2019
2 Reads

Avatrombopag for the treatment of immune thrombocytopenia.

Expert Rev Clin Immunol 2019 Apr 8;15(4):327-339. Epub 2019 Mar 8.

a Department of Hematology , Jagiellonian University , Krakow , Poland.

Introduction: Thrombopoietin-receptor agonists (TPO-RAs) are the only American Society of Hematology (ASH) guideline-advocated, second-line treatment for immune thrombocytopenia (ITP) that have been validated by randomized, controlled trials with a placebo comparator. Avatrombopag is a new candidate in this class that has been investigated as a treatment option for the treatment of ITP. Areas covered: In this Drug Profile, we provide a review of the clinical data of avatrombopag, which was approved in May 2018 by the United States Food and Drug Administration (FDA) for the treatment of thrombocytopenia in patients with chronic liver disease undergoing an invasive procedure, and an opinion of its potential place in the current evidence-based ITP treatment landscape. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1587294DOI Listing
April 2019
2 Reads

The molecular immunology of human susceptibility to fungal diseases: lessons from single gene defects of immunity.

Authors:
Donald C Vinh

Expert Rev Clin Immunol 2019 May 4;15(5):461-486. Epub 2019 Mar 4.

a Department of Medicine (Division of Infectious Diseases; Division of Allergy & Clinical Immunology), Department of Medical Microbiology, Department of Human Genetics , McGill University Health Centre - Research Institute , Montreal , QC , Canada.

Introduction: Fungal diseases are a threat to human health. Therapies targeting the fungus continue to lead to disappointing results. Strategies targeting the host response represent unexplored opportunities for innovative treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1584038DOI Listing

The importance of early peanut ingestion in the prevention of peanut allergy.

Expert Rev Clin Immunol 2019 May 11;15(5):487-495. Epub 2019 Mar 11.

a Jaffe Food Allergy Institute, Division of Pediatric Allergy and Immunology , Icahn School of Medicine at Mount Sinai , New York , NY , USA.

Introduction: Peanut allergy appears to have increased in prevalence, is often severe and is typically life-long. Therefore, reducing its incidence through a primary prevention strategy is a priority. Guidelines on peanut introduction have evolved with time and given evidence of peanut allergy risk reduction with early infant ingestion exposure, the current US advice promotes early introduction for infants, particularly targeting those at highest risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1582331DOI Listing

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018.

Expert Rev Clin Immunol 2019 May 14;15(5):553-569. Epub 2019 Feb 14.

a Division of Research , Matrix45 , Tucson , AZ , USA.

Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma [SAA] in Europe). A 2016 review of 24 real-world effectiveness studies in SAA published between 2008-2015 concluded that omalizumab was associated with significant improvements in objective and subjective outcomes with benefits extending beyond 2 years. Several new real-world studies have been published since, bringing the total to 42 studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1574571DOI Listing
May 2019
1 Read

Abatacept for the treatment of rheumatoid arthritis.

Expert Rev Clin Immunol 2019 Apr 18;15(4):319-326. Epub 2019 Feb 18.

b Fundacion Ramon Dominguez, Hospital Clinico Universitario , Santiago de Compostela , Spain.

Introduction: Rheumatoid arthritis (RA) is a complex disease in which different mechanisms are involved. Studies suggest a key role for aberrant pathways of T-cell activation in the initiation and perpetuation of disease. Abatacept is a fusion protein composed of the Fc region of the immunoglobulin G1 (IgG1) fused to the extracellular domain of cytotoxic T lymphocyte-associated antigen (CTLA4). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1579642DOI Listing
April 2019
11 Reads

Limits of traditional evidence-based medicine methodologies exemplified by the novel era in psoriatic arthritis drug development.

Expert Rev Clin Immunol 2019 May 18;15(5):441-444. Epub 2019 Feb 18.

a Department of Rheumatology and Clinical Immunology , University Medical Center Utrecht , Utrecht , The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1580144DOI Listing
May 2019
2 Reads

Screening children for eosinophilic esophagitis: allergic and other risk factors.

Expert Rev Clin Immunol 2019 Apr 20;15(4):315-318. Epub 2019 Feb 20.

a Division of Allergy & Immunology , Children's Hospital of Philadelphia , Philadelphia , PA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1579643DOI Listing
April 2019
1 Read

Measuring and managing appearance anxiety in patients with systemic sclerosis.

Expert Rev Clin Immunol 2019 Apr 4;15(4):341-346. Epub 2019 Feb 4.

b Department of Psychology , San Diego State University , San Diego , CA , USA.

Introduction: Systemic sclerosis (SSc, scleroderma) is a progressive, autoimmune, connective tissue disease of unknown etiology that can cause changes in appearance in socially important areas of the body (e.g. face and hands). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1573673DOI Listing
April 2019
2 Reads

CD40 ligand deficiency: treatment strategies and novel therapeutic perspectives.

Expert Rev Clin Immunol 2019 May 18;15(5):529-540. Epub 2019 Feb 18.

a Department of Immunology, Institute of Biomedical Sciences , University of São Paulo , São Paulo , Brazil.

Introduction: CD40 ligand (CD40L) deficiency or X-linked Hyper-IgM syndrome is a severe primary immunodeficiency caused by mutations in the CD40L gene. Despite currently available treatments, CD40L-deficient patients remain susceptible to life-threatening infections and have poor long term survival. Areas covered: Here, we discuss clinical and immunological characteristics of CD40L deficiency as well as current therapeutic strategies used for patient management. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1573674DOI Listing
May 2019
9 Reads

B-cell depleting immunotherapies: therapeutic opportunities and toxicities.

Expert Rev Clin Immunol 2019 May 6;15(5):497-509. Epub 2019 Feb 6.

a Department of Pediatric Hematology and Oncology, Cellular and Gene Therapy , IRCCS Ospedale Pediatrico Bambino Gesù , Rome , Italy.

Introduction: The last few years have witnessed what can certainly be defined as a 'period of renaissance' for immunotherapy in the field of hematological malignancies. In particular, antibody-mediated and cell-mediated immunotherapy have significantly changed the treatment approach of patients with B-cell lymphoproliferative disorders. These therapies, initially employed in patients with refractory/relapsed disease, are now integrated in the treatment of newly diagnosed patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1573672DOI Listing
May 2019
2 Reads

Belatacept in kidney transplantation and its limitations.

Expert Rev Clin Immunol 2019 Apr 7;15(4):359-367. Epub 2019 Feb 7.

a Service de Néphrologie, Hémodialyse , Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes , Grenoble , France.

Introduction: Since the approval of belatacept in 2011 for use in the setting of de novo kidney transplantation, this CD80/86 - CD28 co-stimulation blocker has been shown to be a valuable treatment option for maintenance immunosuppression. Areas covered: In this setting, belatacept has been associated with superior glomerular filtration rate as compared to calcineurin inhibitor-based treatments because of the absence of nephrotoxicity. Additionally, belatacept avoids the cardiovascular side effects (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1574570DOI Listing
April 2019
2 Reads

Diagnosing autoimmune encephalitis based on clinical features and autoantibody findings.

Authors:
Christian G Bien

Expert Rev Clin Immunol 2019 May 5;15(5):511-527. Epub 2019 Mar 5.

a Epilepsy Center Bethel, Krankenhaus Mara , Bielefeld , Germany.

Introduction: Autoimmune encephalitides have been accepted as a reproducible and treatable new group of diseases. At present, there is concern that such diagnoses might be made too liberally. Areas covered: This article suggests how to make valid diagnoses. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1573676DOI Listing
May 2019
10 Reads

Pain and affective distress in arthritis: relationship to immunity and inflammation.

Expert Rev Clin Immunol 2019 May 11;15(5):541-552. Epub 2019 Feb 11.

b Lawson Health Research Institute , London , Ontario , Canada.

Introduction: Most arthritides are associated with pain and psychological distress (clinically significant depression and anxiety). Pain and depression are mutually exacerbating; both may continue even when joint involvement appears well controlled. Area covered: There is strong evidence that arthritis-related stress impacts the central nervous system and, together with peripheral inflammatory changes, can cause central sensitization that can lead to chronic pain and worsening of affective distress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1573675DOI Listing
May 2019
2 Reads

Canakinumab for the treatment of hyperimmunoglobulin D syndrome.

Expert Rev Clin Immunol 2019 Mar 26;15(3):215-220. Epub 2019 Jan 26.

b Pediatric Rheumatology Unit, Pediatrics Department, Hospital Sant Joan de Déu , Universitat de Barcelona , Barcelona , Spain.

Introduction: Mevalonate Kinase Deficiency (MKD) is a rare monogenic autoinflammatory disorder (AID) with autosomal recessive inheritance caused by mutations in the MVK gene. It includes hyperimmunoglobulinemia D syndrome (HIDS) and mevalonic aciduria (a severe form). Patients have recurrent inflammatory attacks with high fever, gastrointestinal symptoms, lymphadenopathy, splenomegaly, arthralgia, rash, pharyngitis, aphtosis and constitutional complaints. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1571410DOI Listing
March 2019
15 Reads

B cells and atherosclerosis in systemic lupus erythematosus.

Expert Rev Clin Immunol 2019 Apr 8;15(4):417-429. Epub 2019 Feb 8.

a Department of Physiology, School of Medicine , National and Kapodistrian University of Athens , Athens , Greece.

Introduction: Cardiovascular (CV) events, as a result of accelerated atherosclerosis, are an important cause of mortality in patients with Systemic lupus erythematosus (SLE). The etiology of SLE is multifactorial and still unclear; among other potential culprits, excessive B cell activation seems to play a crucial role. Accumulating evidence supports a contributory role of B cells in the pathogenesis of atherosclerosis as well. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1571411DOI Listing
April 2019
2 Reads

Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis.

Expert Rev Clin Immunol 2019 Apr 26;15(4):391-405. Epub 2019 Jan 26.

a Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Department of Autoimmune Diseases , ICMiD, Hospital Clínic , Barcelona , Spain.

Introduction: Sarcoidosis is a complex systemic disease with a silent, long-term evolution, and a heterogeneous clinical presentation. The diagnostic approach is complex with no single diagnostic test that may confirm the disease. Areas covered: A large list of serum biomarkers has been tested during the last 40 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1568240DOI Listing
April 2019
17 Reads

Epidemiology, characterization, and diagnosis of neuropsychiatric events in systemic lupus erythematosus.

Expert Rev Clin Immunol 2019 Apr 14;15(4):407-416. Epub 2019 Jan 14.

b Laboratory of Autoimmune Diseases, School of Medical Science , University of Campinas , Campinas , Brazil.

Introduction: Neuropsychiatric systemic lupus erythematosus (NPSLE) is characterized by a heterogeneity of clinical manifestations. The absence of diagnostic criteria and the lack of clinical trials is a challenge in clinical practice. Areas covered: A literature review was performed to describe epidemiology, characterization (clinical, immunological, and imaging), diagnosis and treatment of NPSLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1564040DOI Listing
April 2019
3 Reads

Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness.

Expert Rev Clin Immunol 2019 Mar 4;15(3):241-250. Epub 2019 Feb 4.

e Cumming School of Medicine , University of Calgary , Calgary , Canada.

Introduction: Anti-DFS70 antibodies and their clinical associations remain an immunological paradox. Unlike other antinuclear antibodies (ANA), there is a growing body of evidence that anti-DFS70 antibodies, when present in high titers and in isolation (without accompanying other antibodies), are useful to aid in the exclusion of ANA associated rheumatic diseases. Areas covered: This review aims to analyze and interpret the current published knowledge and recent findings to provide guidance in the use of anti-DFS70 antibodies to analyze associations of this unique autoantibody. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1562903DOI Listing
March 2019
10 Reads

Management of pregnant women with antiphospholipid antibodies.

Expert Rev Clin Immunol 2019 Apr 11;15(4):347-358. Epub 2019 Jan 11.

a Rheumatology Unit, Department of Medicine , University Hospital of Padua , Padua , Italy.

Introduction: Important advancements in pregnancy outcome have been reported in women with antiphospholipid antibodies (aPL), despite the fact that the treatment of aPL related pregnancy morbidity is not guided by consistent findings from well-designed trials. Areas covered: The current study draws a picture of the studies in the literature by performing a Medline search of relevant English language articles and reports our experience in managing different subsets of obstetric antiphospholipid syndrome (APS), defined on the basis of their clinical and laboratory characteristics. The management of pregnant women with non-criteria APS manifestations and that of aPL carriers during their first pregnancy is also examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1565995DOI Listing
April 2019
3 Reads

Exercise-induced anaphylaxis: causes, consequences, and management recommendations.

Expert Rev Clin Immunol 2019 Mar 9;15(3):265-273. Epub 2019 Jan 9.

a Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA) , Odense University Hospital , Odense , Denmark.

Introduction: Exercise-induced anaphylaxis (EIA) denotes a range of disorders where anaphylaxis occurs in relation to physical exercise. Typical symptoms include flushing, pruritus, urticaria, angioedema, respiratory symptoms, gastrointestinal symptoms, hypotension, and collapse during or after exercise. The far best described entity within EIA is food-dependent exercise-induced anaphylaxis (FDEIA), where symptoms only occur in combination with food intake. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1562904DOI Listing
March 2019
8 Reads

The immunomodulatory role of interleukin-35 in fibrotic diseases.

Expert Rev Clin Immunol 2019 Apr 11;15(4):431-439. Epub 2019 Jan 11.

d Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine , University of Alabama at Birmingham , Birmingham , AL , USA.

Introduction: Fibrosis makes numerous diseases in all organs more complicated and leads to severe consequences in the lung, liver, heart, kidney, and skin. In essence, fibrosis results from excessive, persistent and oftentimes nonreversible aggregation of extracellular matrix (ECM) or simply as collagen during the process of tissue injury and repair. Recent studies suggest the pathology of fibrosis, especially in pulmonary and liver fibrosis, involves various types of immune cells and soluble mediators including interleukin (IL)-35, a recently identified heterodimeric cytokine that belongs to the IL-12 cytokine family. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1564041DOI Listing
April 2019
2 Reads
3.342 Impact Factor

Ixekizumab for the treatment of psoriasis: an update on new data since first approval.

Expert Rev Clin Immunol 2018 Dec 27:1-11. Epub 2018 Dec 27.

a Copenhagen Research Group for Inflammatory Skin (CORGIS), Department of Dermatology and Allergy, Herlev and Gentofte Hospital , University of Copenhagen , Hellerup , Denmark.

Introduction: Psoriasis is a chronic immune-mediated skin disease with a multifactorial etiology. Studies have shown that the inflammatory cytokine interleukin-17A (IL-17A) is a key mediator in the pathogenesis. Targeted biologics have changed the outcome for patients in a variety of diseases including psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1559730DOI Listing
December 2018
4 Reads

Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists.

Expert Rev Clin Immunol 2019 Mar 27;15(3):211-213. Epub 2018 Dec 27.

a Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1559731DOI Listing
March 2019
1 Read

Topical agents for the treatment of atopic dermatitis.

Expert Rev Clin Immunol 2019 Apr 8;15(4):369-382. Epub 2019 Jan 8.

a Department of Dermatology , Icahn School of Medicine , New York , NY , USA.

Introduction: Atopic dermatitis (AD) is perhaps the most common inflammatory skin disorder worldwide, with an increasing incidence in developed countries. The mainstay treatment for patients with AD is topical therapies, which are used not only by the mild patients but also by the moderate-to-severe patients, in conjunction with systemic treatment. While topical steroids and calcineurin antagonists are widely used, these are associated with long-term cutaneous adverse effects (AEs) or a black box warning, preventing their chronic use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1564038DOI Listing
April 2019
4 Reads

Association of TNF, IL12, and IL23 gene polymorphisms and psoriatic arthritis: meta-analysis.

Expert Rev Clin Immunol 2019 Mar 24;15(3):303-313. Epub 2019 Jan 24.

a Postgraduate Program in Biosciences and Physiopathology, Department of Clinical Analysis and Biomedicine , Maringá State University , Maringá , Brazil.

Background: Psoriatic arthritis (PsA) is a chronic skin and joint condition that considerably affects patient quality of life. Several studies have demonstrated different associations of genetic polymorphisms in the pathogenic process of PsA. Therefore, we conducted a meta-analysis to estimate the effect of polymorphisms in the cytokines TNF, IL12B, IL23A, and IL23R on PsA risk. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1564039DOI Listing
March 2019
22 Reads

Infusion-related reactions to rituximab: frequency, mechanisms and predictors.

Expert Rev Clin Immunol 2019 Apr 11;15(4):383-389. Epub 2019 Jan 11.

a Département d'Hématologie Clinique , CHRU de Montpellier , Montpellier , France.

Introduction: Rituximab, an anti-CD20 monoclonal antibody (mAb), is indicated in the treatment of B-cell non-Hodgkin lymphomas, chronic lymphoid leukemia, and rheumatoid arthritis. The occurrence of infusion-related reactions (IRR), especially during the first infusion, is one of the main concerns of rituximab, otherwise well tolerated. Although IRR are usually mild to moderate, fatal evolutions have been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1562905DOI Listing
April 2019
2 Reads

Atopic dermatitis: a review of evolving targeted therapies.

Expert Rev Clin Immunol 2019 Mar 14;15(3):275-288. Epub 2019 Jan 14.

a Department of Internal Medicine , University of North Dakota School of Medicine and Health Sciences , Bismarck , ND , USA.

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin condition, affecting a significant number of patients of all ages. As we learn more about the pathogenesis of AD, new targeted treatment options are being developed to better tailor its management. Currently, a variety of biologic agents are utilized to target specific components and regulators of the inflammatory pathways in allergic and inflammatory conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1560267DOI Listing
March 2019
2 Reads

The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.

Expert Rev Clin Immunol 2019 02 8;15(2):123-134. Epub 2019 Jan 8.

a NIHR Leeds Biomedical Research Centre , Leeds Teaching Hospitals NHS Trust , Leeds , UK.

Introduction: Secukinumab, an interleukin-17A (IL-17A) antagonist, is the first non-TNF alpha inhibitor agent licensed for ankylosing spondylitis (AS), which opens up a new era of alternative cytokine targets beyond TNF. Areas covered: This review explores the pathophysiology and scientific evidence behind the use of this new mode of action and discusses the basis for its efficacy and clinical utility in the management of AS. In particular, how the emergent data points towards the efficacy of secukinumab and ixekizumab, a second emergent IL-17A blocker, in AS has helped focus research into the IL-23/17 axis in entheseal driven disease in man and how IL-17A inhibition may be linked to the presence of innate and adaptive immune cell populations capable of IL-17A elaboration in these target tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1561281DOI Listing
February 2019
6 Reads

New frontiers in precision medicine for sepsis-induced immunoparalysis.

Expert Rev Clin Immunol 2019 Mar 7;15(3):251-263. Epub 2019 Jan 7.

a Department of Intensive Care Medicine , Radboud University Medical Center , Nijmegen , The Netherlands.

Introduction: In the last decade, the sepsis research field has shifted focus from targeting hyperinflammation to reversing sepsis-induced immunoparalysis. Sepsis-induced immunoparalysis is very heterogeneous: the magnitude and the nature of the underlying immune defects differ considerably between patients, but also within individuals over time. Therefore, a 'one-treatment-fits-all' strategy for sepsis-induced immunoparalysis is bound to fail, and an individualized 'precision medicine' approach is required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1562336DOI Listing
March 2019
6 Reads

New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.

Expert Rev Clin Immunol 2019 Mar 2;15(3):289-301. Epub 2019 Jan 2.

a Department of Biochemical and Clinical Diagnostic , IRCCS SDN , Naples , Italy.

Introduction: High-resolution imaging is the gold standard to measure the functional and biological features of bone lesions. Imaging markers have allowed the characterization both of tumour heterogeneity and metabolic data. Besides, ongoing studies are evaluating a combined use of 'imaging markers', such as SUVs, MATV, TLG, ADC from PET and MRI techniques respectively, and several 'biomarkers' spanning from chemokine immune-modulators, such as PD-1, RANK/RANKL, CXCR4/CXCL12 to transcription factors, such as TP53, RB1, MDM2, RUNX family, EZH2, YY1, MAD2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1561283DOI Listing
March 2019
3 Reads

From mother to baby: antenatal exposure to monoclonal antibody biologics.

Expert Rev Clin Immunol 2019 Mar 24;15(3):221-229. Epub 2019 Jan 24.

i Departments of Pediatrics and Community Health & Epidemiology , Dalhousie University , Halifax , NS , Canada.

Introduction: More women with autoimmune and inflammatory conditions are being treated with monoclonal antibody biologics (mAbs) during their pregnancy, to maintain clinical remission. The use of anti-tumor necrosis factor alpha agents in pregnancy appears to be safe but less is known regarding other mAbs, such as anti-integrins and anti-cytokine agents. There are currently no comprehensive guidelines on how to manage the exposed infants. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1561282DOI Listing
March 2019
35 Reads

New insights into the pathophysiology of IgG4-related disease and markers of disease activity.

Expert Rev Clin Immunol 2019 Mar 27;15(3):231-239. Epub 2018 Dec 27.

a Division of Rheumatology, Department of Internal Medicine , Kanazawa University Graduate School of Medicine , Kanazawa , Japan.

Introduction: Recently, IgG4-related disease (IgG4-RD) has become a well-recognized clinical entity, although its causes are still not well understood. The pathophysiology of IgG4-RD has been reported from a variety of aspects. Areas covered: In this review, we outline a number of recent advances in our understanding of the pathogenesis of IgG4-RD, divided according to acquired immunology and innate immunology and other topics. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1560268DOI Listing
March 2019
17 Reads

Measuring disease activity and response to treatment in rheumatoid arthritis.

Expert Rev Clin Immunol 2018 Dec 17. Epub 2018 Dec 17.

b Department of Musculoskeletal Biology , Institute of Ageing and Chronic Disease, University of Liverpool, Clinical Sciences Centre, Aintree University Hospital , Liverpool.

Introduction: Effective treatment of rheumatoid arthritis (RA) requires suppression of the underlying inflammation. Measurement of such inflammation, the disease activity, is mandatory to target treatment and maximize outcomes. However, this is not as straightforward as it may seem. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1559050DOI Listing
December 2018
11 Reads

Allergen immunotherapy for food allergy from the Asian perspective: key challenges and opportunities.

Expert Rev Clin Immunol 2018 Nov 29. Epub 2018 Nov 29.

a Department of Paediatrics , The Chinese University of Hong Kong, , Prince of Wales Hospital Shatin , New Territories , Hong Kong.

Introduction: Prevalence of food allergy is rising in different regions of the world. Asia has not been spared from this epidemic, but epidemiological data have revealed a different pattern of food allergens in this continent. Allergen-specific immunotherapy (AIT) for food allergy (FA), which has been revolutionary as the main focus of research in recent years, needs to be adapted for the different populations in Asia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1554432DOI Listing
November 2018
10 Reads

Cytokines: the yin and yang of vitiligo pathogenesis.

Expert Rev Clin Immunol 2019 02 30;15(2):177-188. Epub 2018 Nov 30.

a Department of Biochemistry, Faculty of Science , The Maharaja Sayajirao University of Baroda , Vadodara , India.

Introduction: Dysregulation of melanocyte function is associated with vitiligo, an idiopathic autoimmune hypopigmentary skin disorder, caused by the selective destruction of melanocytes. Cytokines, the key mediators of immune response, which are pivotal in maintaining immune homeostasis, are crucial in vitiligo pathogenesis. Several studies indicate that there is an imbalance between pro- and anti-inflammatory cytokines in the skin and serum of vitiligo patients. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1550358DOI Listing
February 2019
14 Reads